Marker Therapeutics, Inc. has announced a collaboration with Cellipont Bioservices to support the cGMP manufacturing of MT-601, its lead Multi-Antigen Recognizing (MAR)-T cell therapy, currently in ...
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company focusing on next-generation T cell immunotherapies, announced that CEO Dr. Juan Vera will participate in a live webcast on May 28, ...
For decades, dogma dictated that the immune system consisted of two separate branches. Cells of the innate system respond rapidly to molecular patterns shared by a broad array of pathogens. Meanwhile, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback